Prexasertib
- Generic Name
- Prexasertib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C18H19N7O2
- CAS Number
- 1234015-52-1
- Unique Ingredient Identifier
- 820NH671E6
- Background
Prexasertib has been used in trials studying the treatment and basic science of mCRPC, Leukemia, Neoplasm, breast cancer, and Ovarian Cancer, among others.
- Associated Conditions
- -
- Associated Therapies
- -
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Acrivon Therapeutics granted 61,950 stock options to employees under its 2023 Inducement Plan, with 25% vesting after one year and 2.083% monthly thereafter. The company develops precision oncology drugs using its AP3 platform, with lead candidate ACR-368 targeting CHK1/CHK2 in a Phase 2 trial. The FDA has granted Fast Track and Breakthrough Device designations for ACR-368. Acrivon reported positive clinical data for ovarian and endometrial cancers, with a 62.5% response rate in endometrial cancer.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath